{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:29:57Z","timestamp":1788445797280,"version":"build-2803163510"},"reference-count":209,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The NLRP3 inflammasome plays a pivotal role in innate immune responses and has emerged as an important contributor to the pathogenesis of cardiovascular diseases (CVDs), including atherosclerosis, heart failure, myocardial infarction, and hypertension-related organ damage. Upon activation, NLRP3 promotes the maturation and release of IL-1\u03b2 and IL-18 and triggers pyroptosis, thereby exacerbating endothelial dysfunction, vascular smooth muscle cell proliferation and migration, lipid metabolic disorders, and adverse myocardial remodeling. These processes form a self-perpetuating cycle of inflammation and tissue injury. Therapeutic strategies targeting the NLRP3 pathway have progressed from non-specific anti-inflammatory agents, such as aspirin and colchicine, to more precise interventions that block NLRP3 oligomerization (e.g., MCC950 and its analogs), neutralize upstream cytokines, modulate metabolic and oxidative stress pathways, and employ advanced delivery systems including gene editing and nanocarriers. Despite these advances, current approaches are limited by insufficient target specificity, incomplete long-term safety data, and the absence of disease subtype-specific regimens. This review provides a comprehensive overview of multi-level therapeutic strategies directed against the NLRP3 inflammasome, critically evaluates preclinical and clinical evidence\u2014including findings from the CANTOS trial\u2014and discusses the translational potential of NLRP3-targeted immunometabolic therapy in CVDs. Looking forward, integration of multi-omics technologies, such as single-cell sequencing and spatial transcriptomics, with well-designed clinical studies will be essential to delineate the context-specific roles of NLRP3 across different CVD subtypes and to clarify its interactions with protective pathways such as AMPK and SIRT1. These efforts may facilitate the development of more selective, tissue-targeted, and safer therapeutic agents for the precision management of cardiovascular diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1848762","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:58:57Z","timestamp":1785844737000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["NLRP3 inflammasome in cardiovascular diseases: molecular mechanisms and advances in targeted drug research"],"prefix":"10.3389","volume":"17","author":[{"given":"Tianqing","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Cardiology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People\u2019s Hospital of Changde city)","place":["Changde, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People\u2019s Hospital of Changde city)","place":["Changde, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailin","family":"Yang","sequence":"additional","affiliation":[{"name":"Institute of Basic Research in Traditional Chinese Medicine, Hunan Academy of Chinese Medicine","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglan","family":"Liu","sequence":"additional","affiliation":[{"name":"Changde Hospital Affiliated to Hengyang Medical College, University of South China","place":["Changde, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijie","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, The First People\u2019s Hospital of Changde City","place":["Changde, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Changde Hospital Affiliated to Hengyang Medical College, University of South China","place":["Changde, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for Cardiometabolic Science, University of Louisville","place":["Louisville, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People\u2019s Hospital of Changde city)","place":["Changde, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangqing","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People\u2019s Hospital of Changde city)","place":["Changde, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2022.08.005","article-title":"Progress in cardiovascular diseases statistics 2022","volume":"73","author":"Lavie","year":"2022","journal-title":"Prog Cardiovasc Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/02601060231216523","article-title":"Dietary patterns and the risk of cardiovascular diseases","volume":"29","author":"Ahmad","year":"2023","journal-title":"Nutr Health"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2174\/1568026622666220201151248","article-title":"The design of multi-target drugs to treat cardiovascular diseases: Two(or more) birds on one stone","volume":"22","author":"Caruso","year":"2022","journal-title":"Curr Top Med Chem"},{"key":"B4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ctm2.13","article-title":"NLRP3 inflammasome, an immune\u2010inflammatory target in pathogenesis and treatment of cardiovascular diseases","volume":"10","author":"Wang","year":"2020","journal-title":"Clin Transl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11655-024-3655-2","article-title":"Effects of NLRP3 inflammasome mediated pyroptosis on cardiovascular diseases and intervention mechanism of Chinese medicine","volume":"30","author":"Zhong","year":"2024","journal-title":"Chin J Integr Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yjmcc.2025.09.006","article-title":"Targeting the NLRP3 inflammasome-Gasdermin D axis to combat cardiovascular diseases","volume":"209","author":"Choi","year":"2025","journal-title":"J Mol Cell Cardiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/med.21781","article-title":"NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications","volume":"41","author":"Pellegrini","year":"2021","journal-title":"Med Res Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-023-00946-3","article-title":"The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases","volume":"21","author":"Toldo","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.03.379","article-title":"Inflammasome signaling in atrial fibrillation","volume":"79","author":"Ajoolabady","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175091","article-title":"Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome","volume":"928","author":"Li","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41419-020-02985-x","article-title":"NLRP3 inflammasome in endothelial dysfunction","volume":"11","author":"Bai","year":"2020","journal-title":"Cell Death Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117615","article-title":"NLRP3 inhibition protects human coronary endothelial cells from oxidative and lipotoxic stress","volume":"244","author":"Parenti","year":"2026","journal-title":"Biochem Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11101958","article-title":"Roles of oxidative stress and inflammation in vascular endothelial dysfunction-related disease","volume":"11","author":"Higashi","year":"2022","journal-title":"Antioxidants"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/antiox14030256","article-title":"Endothelial dysfunction: redox imbalance, NLRP3 inflammasome, and inflammatory responses in cardiovascular diseases","volume":"14","author":"Penna","year":"2025","journal-title":"Antioxidants"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.108053","article-title":"Targeting the NLRP3 inflammasome in cardiovascular diseases","volume":"236","author":"Toldo","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122998","article-title":"Myocardial ischemia-reperfusion injury: The balance mechanism between mitophagy and NLRP3 inflammasome","volume":"355","author":"Chen","year":"2024","journal-title":"Life Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-025-02220-z","article-title":"The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications","volume":"10","author":"Wang","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0761-3","article-title":"PtdIns4P on dispersed trans-Golgi network mediates NLRP3 inflammasome activation","volume":"564","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/art.41245","article-title":"Direct binding to NLRP3 pyrin domain as a novel strategy to prevent NLRP3\u2010driven inflammation and gouty arthritis","volume":"72","author":"Yang","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00125-024-06306-1","article-title":"Targeting the NLRP3 inflammasome\u2013IL-1\u03b2 pathway in type 2 diabetes and obesity","volume":"68","author":"Meier","year":"2025","journal-title":"Diabetologia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-018-0055-7","article-title":"Inflammasome signalling in brain function and neurodegenerative disease","volume":"19","author":"Heneka","year":"2018","journal-title":"Nat Rev Neurosci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1568722","article-title":"The NLRP3 inflammasome: a therapeutic target of phytochemicals in treating atherosclerosis (a systematic review)","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189271","article-title":"Regulation of NLRP3\/TRIM family signaling in gut inflammation and colorectal cancer","volume":"1880","author":"Mohapatra","year":"2025","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"793519716","DOI":"10.3410\/f.726105152.793519716","article-title":"Faculty Opinions recommendation of NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux","author":"Latz","year":"2016","journal-title":"Faculty Opin"},{"key":"B27","doi-asserted-by":"publisher","first-page":"793519717","DOI":"10.3410\/f.725996390.793519717","article-title":"Faculty Opinions recommendation of NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component","author":"Latz","year":"2016","journal-title":"Faculty Opin"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1303424","article-title":"A critical role for human caspase-4 in endotoxin sensitivity","volume":"193","author":"Kajiwara","year":"2014","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nature10558","article-title":"Non-canonical inflammasome activation targets caspase-11","volume":"479","author":"Kayagaki","year":"2011","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nature13683","article-title":"Inflammatory caspases are innate immune receptors for intracellular LPS","volume":"514","author":"Shi","year":"2014","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41421-020-0167-x","article-title":"Inflammasome activation and regulation: toward a better understanding of complex mechanisms","volume":"6","author":"Zheng","year":"2020","journal-title":"Cell Discov"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-021-00098-4","article-title":"Autophagy in healthy aging and disease","volume":"1","author":"Aman","year":"2021","journal-title":"Nat Aging"},{"key":"B33","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41419-019-1413-8","article-title":"Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors","volume":"10","author":"Yang","year":"2019","journal-title":"Cell Death Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2025.04.007","article-title":"Targeting the NLRP3 inflammasome for inflammatory disease therapy","volume":"46","author":"Cabral","year":"2025","journal-title":"Trends Pharmacol Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14205","article-title":"The current role of NLRP3 inflammasome polymorphism in gout susceptibility","volume":"24","author":"Clavijo\u2010Cornejo","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116667","article-title":"The NLRP3 inflammasome: A central player in multiple sclerosis","volume":"232","author":"Ot\u00e1lora-Alcaraz","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-025-03972-x","article-title":"The role of NLRP3 inflammasome activation in proinflammatory and cytotoxic effects of metal nanoparticles","volume":"99","author":"Aschner","year":"2025","journal-title":"Arch Toxicol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1611719","article-title":"Regulation of cancer by inflammasomes: from inflammation to tumorigenesis","volume":"16","author":"Malvankar","year":"2025","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115542","article-title":"Discovery of a novel 1,3,4-oxadiazol-2-one-based NLRP3 inhibitor as a pharmacological agent to mitigate cardiac and metabolic complications in an experimental model of diet-induced metaflammation","volume":"257","author":"Gastaldi","year":"2023","journal-title":"Eur J Med Chem"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nature21363","article-title":"Inflammation, metaflammation and immunometabolic disorders","volume":"542","author":"Hotamisligil","year":"2017","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1042\/BCJ20190472","article-title":"The NLRP3 inflammasome regulates adipose tissue metabolism","volume":"477","author":"Barra","year":"2020","journal-title":"Biochem J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2279","article-title":"The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance","volume":"17","author":"Vandanmagsar","year":"2011","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02230-7","article-title":"The expanding role of the NLRP3 inflammasome from periodic fevers to therapeutic targets","volume":"26","author":"Weber","year":"2025","journal-title":"Nat Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118164","article-title":"Mechanisms and therapeutic potential of pharmacological agents targeting inflammasomes","volume":"189","author":"Li","year":"2025","journal-title":"BioMed Pharmacother"},{"key":"B45","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1124\/pharmrev.122.000629","article-title":"Pharmacological inhibition of the NLRP3 inflammasome: Structure, molecular activation, and inhibitor-NLRP3 interaction","volume":"75","author":"Ma","year":"2023","journal-title":"Pharmacol Rev"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.192.Supp.120.1","article-title":"FADD and caspase-8 mediate priming and activation of the canonical and non-canonical Nlrp3 inflammasomes (INC5P.321)","volume":"192","author":"Gurung","year":"2014","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.652321","article-title":"Caspase-8 as an effector and regulator of NLRP3 inflammasome signaling","volume":"290","author":"Antonopoulos","year":"2015","journal-title":"J Biol Chem"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2025.2594555","article-title":"Breakthroughs of ultrasound-targeted microbubble destruction in treating myocardial ischemia-reperfusion injury: from angiogenesis regulation to precise inflammation suppression","volume":"32","author":"Feng","year":"2025","journal-title":"Drug Delivery"},{"key":"B49","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11883-025-01323-w","article-title":"Cholesterol crystals as triggers of NLRP3 inflammasome activation in atherosclerosis","volume":"27","author":"Yalcinkaya","year":"2025","journal-title":"Curr Atheroscler Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-024-01115-w","article-title":"Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches","volume":"22","author":"Khan","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110098","article-title":"Interleukin-37 ameliorates atherosclerosis by regulating autophagy-mediated endothelial cell apoptosis and inflammation","volume":"118","author":"Xiao","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.08.049","article-title":"MicroRNA-30c-5p inhibits NLRP3 inflammasome-mediated endothelial cell pyroptosis through FOXO3 down-regulation in atherosclerosis","volume":"503","author":"Li","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"B53","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1161\/CIRCRESAHA.118.314402","article-title":"Endothelial Foxp1 suppresses atherosclerosis via modulation of Nlrp3 inflammasome activation","volume":"125","author":"Zhuang","year":"2019","journal-title":"Circ Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102775","article-title":"Endothelial Gata6 deletion reduces monocyte recruitment and proinflammatory macrophage formation and attenuates atherosclerosis through Cmpk2-Nlrp3 pathways","volume":"64","author":"Wu","year":"2023","journal-title":"Redox Biol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.7150\/thno.81388","article-title":"Nicotine exacerbates atherosclerosis and plaque instability via NLRP3 inflammasome activation in vascular smooth muscle cells","volume":"13","author":"An","year":"2023","journal-title":"Theranostics"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.121.317168","article-title":"Caspase-8 promotes pulmonary hypertension by activating macrophage-associated inflammation and IL-1\u03b2 (Interleukin 1\u03b2) production","volume":"42","author":"Rong","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"15156","DOI":"10.1038\/s41598-021-94314-1","article-title":"Extracellular NLRP3 inflammasome particles are internalized by human coronary artery smooth muscle cells and induce pro-atherogenic effects","volume":"11","author":"Gaul","year":"2021","journal-title":"Sci Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.70260","article-title":"Targeting the NLRP3 inflammasome in atherosclerosis: Advances in anti\u2010inflammatory therapies with bioactive natural products","volume":"40","author":"Guo","year":"2026","journal-title":"Phytother Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1142\/S0192415X23500933","article-title":"Andrographolide attenuates oxidized LDL-induced activation of the NLRP3 inflammasome in bone marrow-derived macrophages and mitigates HFCCD-induced atherosclerosis in mice","volume":"51","author":"Chen","year":"2023","journal-title":"Am J Chin Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.116304","article-title":"Polydatin protects against atherosclerosis by activating autophagy and inhibiting pyroptosis mediated by the NLRP3 inflammasome","volume":"309","author":"Zhang","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12296","article-title":"Thrombosis formation on atherosclerotic lesions and plaque rupture","volume":"276","author":"Badimon","year":"2014","journal-title":"J Intern Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105599","article-title":"Suppression of apoptosis in vascular endothelial cell, the promising way for natural medicines to treat atherosclerosis","volume":"168","author":"Duan","year":"2021","journal-title":"Pharmacol Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jare.2021.06.023","article-title":"Activation of Nrf2\/HO-1 signaling: An important molecular mechanism of herbal medicine in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress","volume":"34","author":"Zhang","year":"2021","journal-title":"J Adv Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155472","article-title":"Traditional Chinese medicine and mitophagy: A novel approach for cardiovascular disease management","volume":"128","author":"Wang","year":"2024","journal-title":"Phytomedicine"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.7002","article-title":"Natural products: The role and mechanism in low\u2010density lipoprotein oxidation and atherosclerosis","volume":"35","author":"Zhang","year":"2021","journal-title":"Phytother Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-018-0812-9","article-title":"Andrographolide ameliorates atherosclerosis by suppressing pro-inflammation and ROS generation-mediated foam cell formation","volume":"41","author":"Wu","year":"2018","journal-title":"Inflammation"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2019.152935","article-title":"Polydatin attenuates atherosclerosis in apolipoprotein E-deficient mice: Role of reverse cholesterol transport","volume":"62","author":"Peng","year":"2019","journal-title":"Phytomedicine"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102511","article-title":"A novel anti-atherosclerotic mechanism of quercetin: Competitive binding to KEAP1 via Arg483 to inhibit macrophage pyroptosis","volume":"57","author":"Luo","year":"2022","journal-title":"Redox Biol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.202000746","article-title":"Quercetin attenuates atherosclerotic inflammation by inhibiting Galectin\u20103\u2010NLRP3 signaling pathway","volume":"65","author":"Li","year":"2021","journal-title":"Mol Nutr Food Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.155002","article-title":"Salvianolic acid B inhibits atherosclerosis and TNF-\u03b1-induced inflammation by regulating NF-\u03baB\/NLRP3 signaling pathway","volume":"119","author":"Zhao","year":"2023","journal-title":"Phytomedicine"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/nature11290","article-title":"Novel role of PKR in inflammasome activation and HMGB1 release","volume":"488","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13280","article-title":"PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation","volume":"7","author":"Xie","year":"2016","journal-title":"Nat Commun"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S1875-5364(23)60506-0","article-title":"Paeonol reduces microbial metabolite \u03b1-hydroxyisobutyric acid to alleviate the ROS\/TXNIP\/NLRP3 pathway-mediated endothelial inflammation in atherosclerosis mice","volume":"21","author":"Liu","year":"2023","journal-title":"Chin J Nat Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2017.10.017","article-title":"Paeoniflorin inhibits VSMCs proliferation and migration by arresting cell cycle and activating HO-1 through MAPKs and NF-\u03baB pathway","volume":"54","author":"Li","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108315","article-title":"Baicalein alleviates pyroptosis and inflammation in hyperlipidemic pancreatitis by inhibiting NLRP3\/Caspase-1 pathway through the miR-192-5p\/TXNIP axis","volume":"101","author":"Wang","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s10787-023-01161-9","article-title":"Oridonin attenuates the progression of atherosclerosis by inhibiting NLRP3 and activating Nrf2 in apolipoprotein E-deficient mice","volume":"31","author":"Wang","year":"2023","journal-title":"Inflammopharmacology"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2022.116011","article-title":"Tongxinluo attenuates atherosclerosis by inhibiting ROS\/NLRP3\/caspase-1-mediated endothelial cell pyroptosis","volume":"304","author":"Jiang","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.117240","article-title":"Xinmaikang (XMK) tablets alleviate atherosclerosis by regulating the SREBP2-mediated NLRP3\/ASC\/Caspase-1 signaling pathway","volume":"319","author":"Hou","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e20026","article-title":"Zhilong Huoxue Tongyu capsule inhibits rabbit model of hyperlipidemia and atherosclerosis through NF-\u03baB\/NLRP3 signaling pathway","volume":"9","author":"Liu","year":"2023","journal-title":"Heliyon"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/9131178","article-title":"Biejiajian Pill ameliorates diabetes-associated atherosclerosis through inhibition of the NLRP3 inflammasome","author":"Fu","year":"2022","journal-title":"Evid-based Compl Alt"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.666449","article-title":"Huang-lian-jie-du decoction attenuates atherosclerosis and increases plaque stability in high-fat diet-induced ApoE-\/- mice by inhibiting M1 macrophage polarization and promoting M2 macrophage polarization","volume":"12","author":"Cai","year":"2021","journal-title":"Front Physiol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2022.115787","article-title":"Qingre Huoxue Decoction regulates macrophage polarisation to attenuate atherosclerosis through the inhibition of NF-\u03baB signalling-mediated inflammation","volume":"301","author":"Jin","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70418","article-title":"Acute myocardial infarction: Molecular pathogenesis, diagnosis, and clinical management","volume":"6","author":"Zhu","year":"2025","journal-title":"MedComm"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01394-7","article-title":"Prevention of heart failure after acute myocardial infarction","volume":"406","author":"Udell","year":"2025","journal-title":"Lancet"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2017.161","article-title":"The NLRP3 inflammasome in acute myocardial infarction","volume":"15","author":"Toldo","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1368835","article-title":"NLRP3 inflammasome and pyroptosis in cardiovascular diseases and exercise intervention","volume":"15","author":"Ding","year":"2024","journal-title":"Front Pharmacol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/5867987","article-title":"LuQi Formula ameliorates myocardial fibrosis by suppressing TLR4\/MyD88\/NF-\u03baB pathway and NLRP3 inflammasome activation in mice with myocardial infarction","author":"Zhang","year":"2022","journal-title":"Evid-based Compl Alt"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000709","article-title":"Cell-specific roles of NLRP3 inflammasome in myocardial infarction","volume":"74","author":"Takahashi","year":"2019","journal-title":"J Cardiovasc Pharmacol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jacc.2021.11.002","article-title":"Intramyocardial hemorrhage: the final frontier for preventing heart failure post-myocardial infarction","volume":"79","author":"Berry","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pcad.2024.01.017","article-title":"The spectrum of post-myocardial infarction care: From acute ischemia to heart failure","volume":"82","author":"Akhtar","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-025-02007-2","article-title":"Targeting the NLRP3 inflammasome with natural products for ischemia\u2013reperfusion injury across organs: mechanisms, structure\u2013activity relationships, and delivery innovations","volume":"33","author":"Kumar","year":"2025","journal-title":"Inflammopharmacology"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13186","article-title":"Pyroptosis in neutrophils: Multimodal integration of inflammasome and regulated cell death signaling pathways","volume":"314","author":"Dubyak","year":"2023","journal-title":"Immunol Rev"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020872","article-title":"Structure, activation and regulation of NLRP3 and AIM2 inflammasomes","volume":"22","author":"Sharma","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.123.321637","article-title":"Inflammasomes and atherosclerosis: a mixed picture","volume":"132","author":"Tall","year":"2023","journal-title":"Circ Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2020.111847","article-title":"VX-765 attenuates atherosclerosis in ApoE deficient mice by modulating VSMCs pyroptosis","volume":"389","author":"Li","year":"2020","journal-title":"Exp Cell Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-16-0949","article-title":"Colchicine improves survival, left ventricular remodeling, and chronic cardiac function after acute myocardial infarction","volume":"81","author":"Fujisue","year":"2017","journal-title":"Circ J"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.07.064","article-title":"Targeting inflammation after acute myocardial infarction","volume":"86","author":"Imbesi","year":"2025","journal-title":"JACC"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-023-04812-1","article-title":"Mitochondria and NLRP3 inflammasome in cardiac hypertrophy","volume":"479","author":"Yan","year":"2024","journal-title":"Mol Cell Biochem"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1377359","article-title":"The role of pyroptosis in heart failure and related traditional chinese medicine treatments","volume":"15","author":"Qin","year":"2024","journal-title":"Front Pharmacol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1161\/CIRCULATIONAHA.119.042336","article-title":"SNO-MLP (S-nitrosylation of muscle LIM protein) facilitates myocardial hypertrophy through TLR3 (toll-like receptor 3)\u2013mediated RIP3 (receptor-interacting protein kinase 3) and NLRP3 (NOD-like receptor pyrin domain containing 3) inflammasome activation","volume":"141","author":"Tang","year":"2020","journal-title":"Circulation"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.060860","article-title":"NLRP3 inflammasome activation through heart-brain interaction initiates cardiac inflammation and hypertrophy during pressure overload","volume":"147","author":"Higashikuni","year":"2023","journal-title":"Circulation"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"107511","DOI":"10.1016\/j.pharmthera.2020.107511","article-title":"Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis","volume":"209","author":"Pinar","year":"2020","journal-title":"Pharmacol Ther"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034621","article-title":"Inflammation and NLRP3 inflammasome activation initiated in response to pressure overload by Ca2+ \/calmodulin-dependent protein kinase II \u03b4 signaling in cardiomyocytes are essential for adverse cardiac remodeling","volume":"138","author":"Suetomi","year":"2018","journal-title":"Circulation"},{"key":"B106","doi-asserted-by":"publisher","first-page":"127","DOI":"10.21037\/atm.2020.02.31","article-title":"Blockade of \u03b2-adrenergic signaling suppresses inflammasome and alleviates cardiac fibrosis","volume":"8","author":"Dang","year":"2020","journal-title":"Ann Transl Med"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbadis.2017.10.001","article-title":"The SGK1 inhibitor EMD638683, prevents angiotensin II\u2013induced cardiac inflammation and fibrosis by blocking NLRP3 inflammasome activation","volume":"1864","author":"Gan","year":"2018","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Dis"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2020.09.013","article-title":"Absence of NLRP3 inflammasome in hematopoietic cells reduces adverse remodeling after experimental myocardial infarction","volume":"5","author":"Louwe","year":"2020","journal-title":"JACC: Basic Transl Sci"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.934255","article-title":"Role of NLRP3 inflammasome in myocardial ischemia-reperfusion injury and ventricular remodeling","volume":"28","author":"Shen","year":"2022","journal-title":"Med Sci Monit Int Med J Exp Clin Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2022.02.027","article-title":"Silica nanoparticles induce pyroptosis and cardiac hypertrophy via ROS\/NLRP3\/Caspase-1 pathway","volume":"182","author":"Wang","year":"2022","journal-title":"Free Radic Biol Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/s41419-020-03157-7","article-title":"Membrane nanotubes facilitate the propagation of inflammatory injury in the heart upon overactivation of the \u03b2-adrenergic receptor","volume":"11","author":"Shen","year":"2020","journal-title":"Cell Death Dis"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101523","article-title":"NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy","volume":"34","author":"Zeng","year":"2020","journal-title":"Redox Biol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2019.06.026","article-title":"A novel circular RNA mediates pyroptosis of diabetic cardiomyopathy by functioning as a competing endogenous RNA","volume":"17","author":"Yang","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033438","article-title":"Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure","volume":"7","author":"Van Tassell","year":"2012","journal-title":"PloS One"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1249\/MSS.0000000000001641","article-title":"Effects of exercise on ASC methylation and IL-1 cytokines in heart failure","volume":"50","author":"Butts","year":"2018","journal-title":"Med Sci Sports Exercise"},{"key":"B116","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nrcardio.2018.22","article-title":"Clonal haematopoiesis, IL-1\u03b2, and the NLRP3 inflammasome in HF","volume":"15","author":"Lim","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease","volume":"126","author":"Abbate","year":"2020","journal-title":"Circ Res"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2022.2053813","article-title":"MCC950 ameliorates ventricular arrhythmia vulnerability induced by heart failure","volume":"13","author":"Jiang","year":"2022","journal-title":"Bioengineered"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.727474","article-title":"MCC950, a selective NLRP3 inhibitor, attenuates adverse cardiac remodeling following heart failure through improving the cardiometabolic dysfunction in obese mice","volume":"9","author":"Wang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26123534","article-title":"Preservation of contractile reserve and diastolic function by inhibiting the NLRP3 inflammasome with OLT1177\u00ae (dapansutrile) in a mouse model of severe ischemic cardiomyopathy due to non-reperfused anterior wall myocardial infarction","volume":"26","author":"Aliaga","year":"2021","journal-title":"Molecules"},{"key":"B121","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cophys.2020.09.013","article-title":"Safety of a novel oral NLRP3 inflammasome inhibitor, dapansutrile (OLT1177), in patients with stable heart failure with reduced ejection fraction: P2108","volume":"22","author":"Abbate","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175126","article-title":"Colchicine alleviates inflammation and improves diastolic dysfunction in heart failure rats with preserved ejection fraction","volume":"929","author":"Shen","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.834289","article-title":"Emerging roles of inflammasomes in cardiovascular diseases","volume":"13","author":"Liao","year":"2022","journal-title":"Front Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1161\/circ.132.suppl_3.11727","article-title":"Abstract 11727: Anti-inflammatory treatment with colchicine in acute myocardial infarction: a randomized study","volume":"132","author":"Giannopoulos","year":"2015","journal-title":"Circulation"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.056177","article-title":"Effect of colchicine on myocardial injury in acute myocardial infarction","volume":"144","author":"Mewton","year":"2021","journal-title":"Circulation"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","article-title":"Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure","volume":"13","author":"Byrne","year":"2020","journal-title":"Circ Heart Fail"},{"key":"B127","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bbrc.2017.02.021","article-title":"Triptolide attenuates pressure overload-induced myocardial remodeling in mice via the inhibition of NLRP3 inflammasome expression","volume":"485","author":"Li","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000351179","article-title":"Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation","volume":"126","author":"Wang","year":"2013","journal-title":"Cardiology"},{"key":"B129","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00395-018-0692-z","article-title":"Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function","volume":"113","author":"Audia","year":"2018","journal-title":"Basic Res Cardiol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"793557740","DOI":"10.3410\/f.734698486.793557740","article-title":"Faculty opinions recommendation of anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","author":"Cotter","year":"2019"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004373","article-title":"Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (recently decompensated heart failure anakinra response trial)","volume":"10","author":"Van Tassell","year":"2017","journal-title":"Circ Heart Fail"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014941","article-title":"Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment-elevation myocardial infarction","volume":"9","author":"Abbate","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx374","article-title":"Linking the sympathetic nervous system to the inflammasome: towards new therapeutics for atherosclerotic cardiovascular disease","volume":"39","author":"Karakas","year":"2018","journal-title":"Eur Heart J"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2020.08.020","article-title":"Modulation of interleukin-1 and -18 mediated injury in donation after circulatory death mouse hearts","volume":"257","author":"Quader","year":"2021","journal-title":"J Surg Res"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1111\/jce.15759","article-title":"Atrial fibrillation: Epidemiology, pathophysiology, and clinical complications (literature review)","volume":"34","author":"Bizhanov","year":"2023","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001147","article-title":"Atrial Fibrillation Occurring During Acute Hospitalization: A Scientific Statement From the American Heart Association","volume":"147","author":"Chyou","year":"2023","journal-title":"Circulation"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S422002","article-title":"Effects of inflammatory cell death caused by catheter ablation on atrial fibrillation","volume":"16","author":"Liu","year":"2023","journal-title":"J Inflammation Res"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035202","article-title":"Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation","volume":"138","author":"Yao","year":"2018","journal-title":"Circulation"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1172\/JCI167517","article-title":"Chronic kidney disease promotes atrial fibrillation via inflammasome pathway activation","volume":"133","author":"Song","year":"2023","journal-title":"J Clin Invest"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvab024","article-title":"NLRP3 inflammasome is a key driver of obesity-induced atrial arrhythmias","volume":"117","author":"Scott","year":"2021","journal-title":"Cardiovasc Res"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvab114","article-title":"Gut microbiota dysbiosis promotes age-related atrial fibrillation by lipopolysaccharide and glucose-induced activation of NLRP3-inflammasome","volume":"118","author":"Zhang","year":"2022","journal-title":"Cardiovasc Res"},{"key":"B142","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/CIRCRESAHA.120.316363","article-title":"Molecular basis of atrial fibrillation pathophysiology and therapy: a translational perspective","volume":"127","author":"Nattel","year":"2020","journal-title":"Circ Res"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2022.12.004","article-title":"Fir(e)ing the rhythm: inflammatory cytokines and cardiac arrhythmias","volume":"8","author":"Lazzerini","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.316710","article-title":"Atrial myocyte NLRP3\/CaMKII nexus forms a substrate for postoperative atrial fibrillation","volume":"127","author":"Heijman","year":"2020","journal-title":"Circ Res"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.70644","article-title":"Commensal microbe-derived SCFA alleviates atrial fibrillation via GPR43\/NLRP3 signaling","volume":"18","author":"Zuo","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.06.016","article-title":"Preventive effects of astragaloside IV and its active sapogenin cycloastragenol on cardiac fibrosis of mice by inhibiting the NLRP3 inflammasome","volume":"833","author":"Wan","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx261","article-title":"IL-18 cleavage triggers cardiac inflammation and fibrosis upon \u03b2-adrenergic insult","volume":"39","author":"Xiao","year":"2018","journal-title":"Eur Heart J"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-019-0305-x","article-title":"\u03b11-AR overactivation induces cardiac inflammation through NLRP3 inflammasome activation","volume":"41","author":"Xin","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1113\/EP088390","article-title":"Knockout of MD1 contributes to sympathetic hyperactivity and exacerbates ventricular arrhythmias following heart failure with preserved ejection fraction via NLRP3 inflammasome activation","volume":"105","author":"Yang","year":"2020","journal-title":"Exp Physiol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.121.056171","article-title":"Colchicine in cardiovascular disease: in-depth review","volume":"145","author":"Deftereos","year":"2022","journal-title":"Circulation"},{"key":"B151","doi-asserted-by":"publisher","first-page":"793465541","DOI":"10.3410\/f.717962142.793465541","article-title":"Faculty Opinions recommendation of colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study","author":"Kron","year":"2012"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2014.02.002","article-title":"Colchicine for prevention of atrial fibrillation recurrence after pulmonary vein isolation: mid-term efficacy and effect on quality of life","volume":"11","author":"Deftereos","year":"2014","journal-title":"Heart Rhythm"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvad175","article-title":"An inflammation resolution\u2013promoting intervention prevents atrial fibrillation caused by left ventricular dysfunction","volume":"120","author":"Hiram","year":"2024","journal-title":"Cardiovasc Res"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-021-02115-0","article-title":"Possible protective effect of resolvin D1 on inflammation in atrial fibrillation: involvement of ER stress mediated the NLRP3 inflammasome pathway","volume":"394","author":"Yarmohammadi","year":"2021","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2018.09.238","article-title":"Salvianolate reduces atrial fibrillation through suppressing atrial interstitial fibrosis by inhibiting TGF-\u03b21\/Smad2\/3 and TXNIP\/NLRP3 inflammasome signaling pathways in post-MI rats","volume":"51","author":"Qiu","year":"2018","journal-title":"Phytomedicine"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111536","article-title":"Inhibition of the P2X7 receptor prevents atrial proarrhythmic remodeling in experimental post-operative atrial fibrillation","volume":"129","author":"Ye","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euae022","article-title":"P2X7 receptor inhibition prevents atrial fibrillation in rodent models of depression","volume":"26","author":"Ye","year":"2024","journal-title":"Europace"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2022.102590","article-title":"Blockage of transient receptor potential vanilloid 4 prevents postoperative atrial fibrillation by inhibiting NLRP3-inflammasome in sterile pericarditis mice","volume":"104","author":"Yang","year":"2022","journal-title":"Cell Calcium"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.7150\/thno.89520","article-title":"Inactivation of the NLRP3 inflammasome mediates exosome-based prevention of atrial fibrillation","volume":"14","author":"Parent","year":"2024","journal-title":"Theranostics"},{"key":"B160","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12933-025-02602-1","article-title":"A new kid in town: cardiovascular diabetology-endocrinology reports","volume":"24","author":"Fisman","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176253","article-title":"Berberine inhibits NLRP3 inflammasome activation by regulating mTOR\/mtROS axis to alleviate diabetic cardiomyopathy","volume":"964","author":"Zhong","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413228","article-title":"NLRP3 inflammasome in diabetic cardiomyopathy and exercise intervention","volume":"22","author":"Sun","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01019-8","article-title":"TXNIP: a key protein in the cellular stress response pathway and a potential therapeutic target","volume":"55","author":"Choi","year":"2023","journal-title":"Exp Mol Med"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810632","article-title":"NLRP3 inflammasome\/pyroptosis: a key driving force in diabetic cardiomyopathy","volume":"23","author":"Zhang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.151072","article-title":"MOTS-c regulates the ROS\/TXNIP\/NLRP3 pathway to alleviate diabetic cardiomyopathy","volume":"741","author":"Fu","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101338","article-title":"Autophagy in the diabetic heart: a potential pharmacotherapeutic target in diabetic cardiomyopathy","volume":"68","author":"Dewanjee","year":"2021","journal-title":"Ageing Res Rev"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116790","article-title":"Targeting autophagy in diabetic cardiomyopathy: from molecular mechanisms to pharmacotherapy","volume":"175","author":"Li","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13511","article-title":"Ubiquitin\u2010conjugating enzyme E2 for regulating autophagy in diabetic cardiomyopathy: a mini\u2010review","volume":"16","author":"Zhou","year":"2024","journal-title":"J Diabetes"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104771","article-title":"NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model","volume":"9","author":"Luo","year":"2014","journal-title":"PloS One"},{"key":"B170","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00011-018-1160-9","article-title":"sRAGE attenuates angiotensin II-induced cardiomyocyte hypertrophy by inhibiting RAGE-NF\u03baB-NLRP3 activation","volume":"67","author":"Lim","year":"2018","journal-title":"Inflammation Res"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13464","article-title":"H3 relaxin inhibits the collagen synthesis via ROS\u2010 and P2X7R\u2010mediated NLRP3 inflammasome activation in cardiac fibroblasts under high glucose","volume":"22","author":"Zhang","year":"2018","journal-title":"J Cell Mol Med"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1159\/000481843","article-title":"H3 relaxin protects against myocardial injury in experimental diabetic cardiomyopathy by inhibiting myocardial apoptosis, fibrosis and inflammation","volume":"43","author":"Zhang","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2012.01536.x","article-title":"The therapeutic effect of rosuvastatin on cardiac remodelling from hypertrophy to fibrosis during the end\u2010stage hypertension in rats","volume":"16","author":"Zhang","year":"2012","journal-title":"J Cell Mol Med"},{"key":"B174","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cyto.2010.10.002","article-title":"Effects of interleukin-18 on cardiac fibroblast function and gene expression","volume":"53","author":"Fix","year":"2011","journal-title":"Cytokine"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.550624","article-title":"Mitochondrial NLRP3 protein induces reactive oxygen species to promote Smad protein signaling and fibrosis independent from the inflammasome","volume":"289","author":"Bracey","year":"2014","journal-title":"J Biol Chem"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.907757","article-title":"Signaling pathways related to oxidative stress in diabetic cardiomyopathy","volume":"13","author":"Peng","year":"2022","journal-title":"Front Endocrinol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113664","article-title":"H3 relaxin ameliorates mitochondrial quality control and apoptosis in cardiomyocytes of type 2 diabetic rats via activation of the AMPK pathway","volume":"144","author":"Wang","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.6448","article-title":"Coriolus versicolor alleviates diabetic cardiomyopathy by inhibiting cardiac fibrosis and NLRP3 inflammasome activation","volume":"33","author":"Wang","year":"2019","journal-title":"Phytother Res"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13743","article-title":"Gypenosides improve diabetic cardiomyopathy by inhibiting ROS \u2010mediated NLRP 3 inflammasome activation","volume":"22","author":"Zhang","year":"2018","journal-title":"J Cell Mol Med"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-024-01566-0","article-title":"The role of quercetin in NLRP3-associated inflammation","volume":"32","author":"Wu","year":"2024","journal-title":"Inflammopharmacology"},{"key":"B181","article-title":"Naringenin ameliorates myocardial remodeling by inhibiting NLRP3 inflammasome activation in diabetic mice","volume":"45","author":"He","year":"2021"},{"key":"B182","article-title":"Study on the effect of ursolic acid(UA) on the myopardial fibrosis of experimental diabetic mice","author":"Yang","year":"2013"},{"key":"B183","first-page":"9","article-title":"The protective effect of sapindoside from Sapindus mukorossi Gaertn. on H9C2 cardiomyocyte injury induced by high glucose","volume":"15","author":"Zhu","year":"2019","journal-title":"Asia-Pacific Traditional Med"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1703560","article-title":"Targeting the NLRP3 inflammasome in kidney disease: molecular mechanisms, pathogenic roles, and emerging small-molecule therapeutics","volume":"16","author":"Luo","year":"2025","journal-title":"Front Immunol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.082305","article-title":"Anti-inflammatory compounds parthenolide and bay 11-7082 are direct inhibitors of the inflammasome","volume":"285","author":"Juliana","year":"2010","journal-title":"J Biol Chem"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1042\/CS20160645","article-title":"BAY 11-7082 inhibits the NF-\u03baB and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasis","volume":"131","author":"Irrera","year":"2017","journal-title":"Clin Sci"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome\u2013mediated inflammatory disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nat Med"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-061512-150641","article-title":"IL-1 blockade in autoinflammatory syndromes","volume":"65","author":"Jesus","year":"2014","journal-title":"Annu Rev Med"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"B190","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/nrcardio.2017.152","article-title":"Targeting inflammatory pathways to treat atherosclerosis and cancer","volume":"14","author":"Huynh","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2010.03.022","article-title":"The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates","volume":"223","author":"Fox","year":"2010","journal-title":"J Neuroimmunol"},{"key":"B192","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12974-019-1471-y","article-title":"A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury","volume":"16","author":"Kuwar","year":"2019","journal-title":"J Neuroinflamm"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.3A0114-005RR","article-title":"Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation","volume":"96","author":"Honda","year":"2014","journal-title":"J Leukocyte Biol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2008.01.032","article-title":"Isoliquiritigenin isolated from the roots of glycyrrhiza uralensis inhibits LPS-induced iNOS and COX-2 expression via the attenuation of NF-kappaB in RAW 264.7 macrophages","volume":"584","author":"Kim","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200900531","article-title":"A highly potent and selective caspase 1 inhibitor that utilizes a key 3\u2010cyanopropanoic acid moiety","volume":"5","author":"Boxer","year":"2010","journal-title":"ChemMedChem"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.111344","article-title":"(S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2 R,3 S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme\/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1\u03b2 and IL-18","volume":"321","author":"Wannamaker","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat Med"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500865","article-title":"Internalized Cryptococcus neoformans activates the canonical caspase-1 and the noncanonical caspase-8 inflammasomes","volume":"195","author":"Chen","year":"2015","journal-title":"J Immunol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171419","article-title":"Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders","volume":"214","author":"Jiang","year":"2017","journal-title":"J Exp Med"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2022.128693","article-title":"Design and synthesis of an N-benzyl 5-(4-sulfamoylbenzylidene-2-thioxothiazolidin-4-one scaffold as a novel NLRP3 inflammasome inhibitor","volume":"65","author":"Zuo","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"B201","doi-asserted-by":"publisher","first-page":"793544792","DOI":"10.3410\/f.732583597.793544792","article-title":"Faculty Opinions recommendation of OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation","author":"Krause","year":"2018"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105447","article-title":"Pyroptosis is a critical immune-inflammatory response involved in atherosclerosis","volume":"165","author":"He","year":"2021","journal-title":"Pharmacol Res"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2021.10.014","article-title":"Inhibitory effects of sulforaphane on NLRP3 inflammasome activation","volume":"140","author":"Kiser","year":"2021","journal-title":"Mol Immunol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1038\/srep24399","article-title":"A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet","volume":"6","author":"Yang","year":"2016","journal-title":"Sci Rep"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.3A0415-155RR","article-title":"Sulforaphane inhibits multiple inflammasomes through an Nrf2-independent mechanism","volume":"99","author":"Greaney","year":"2016","journal-title":"J Leukocyte Biol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101310","article-title":"Entrectinib inhibits NLRP3 inflammasome and inflammatory diseases by directly targeting NEK7","volume":"4","author":"Jin","year":"2023","journal-title":"Cell Rep Med"},{"key":"B207","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1182\/blood-2023-182060","article-title":"HT-6184 inhibits the formation of the NLRP3 inflammasome in human monocytic THP-1 cells","volume":"142","author":"Bearss","year":"2023","journal-title":"Blood"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2025.107487","article-title":"Macrophage and cardiomyocyte roles in cardioprotection: exploiting the NLRP3 inflammasome inhibitor INF150","volume":"159","author":"Giordano","year":"2025","journal-title":"VascPharmacol"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2024.107397","article-title":"Novel NLRP3 inhibitor INF195: low doses provide effective protection against myocardial ischemia\/reperfusion injury","volume":"156","author":"Gastaldi","year":"2024","journal-title":"VascPharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1848762\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:59:00Z","timestamp":1785844740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1848762\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":209,"alternative-id":["10.3389\/fimmu.2026.1848762"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1848762","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"article-number":"1848762"}}